Most Accessed Articles
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
, 2013; 13(3): 326-346.Ziyad Binkhathlan and Afsaneh Lavasanifar
DOI: 10.2174/15680096113139990076
Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
, 2018; 18(4): 306-327.Heena Singla, Anjana Munshi*, Raja Paramjit Singh Banipal and Vinod Kumar*
DOI: 10.2174/1568009617666170623122213
Potential Anti-cancer Drugs Commonly Used for Other Indications
, 2015; 15(1): 35-52.Veronika Hanusova, Lenka Skalova, Vera Kralova and Petra Matouskova
DOI: 10.2174/1568009615666141229152812
Tunneling Nanotubes: A Versatile Target for Cancer Therapy
, 2018; 18(6): 514-521.Pragyaparamita Sahu, Soumya Ranjan Jena and Luna Samanta*
DOI: 10.2174/1568009618666171129222637
Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
, 2016; 16(1): 43-52.E. P. Spugnini, T. Azzarito, S. Fais, M. Fanciulli and A. Baldi
DOI: 10.2174/156800961601151218155340
Towards Prevention of Ovarian Cancer
, 2018; 18(6): 522-537.Aus Tariq Ali*
DOI: 10.2174/1568009618666180102103008
Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
, 2018; 18(3): 222-230.J. Barroca-Ferreira, J.P. Pais, M.M. Santos, A.M. Goncalves, I.M. Gomes, I. Sousa, S.M. Rocha, L.A. Passarinha and C.J. Maia*
DOI: 10.2174/1568009617666170427103732
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
, 2017; 17(7): 637-649.Sarah L. Sammons, Donna L. Topping and Kimberly L. Blackwell*
DOI: 10.2174/1568009617666170330120452
The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
, 2018; 18(4): 355-364.Dearbhaile C. Collins, Maxime Chenard-Poirier and Juanita S. Lopez*
DOI: 10.2174/1568009617666170927114440
Webmaster Contact: info@benthamscience.org